MediciNova’s MS Candidate Earns Fast Track Status

MediciNova has received FDA fast track designation for MN-166 (ibudilast) to treat neurodegeneration linked to progressive multiple sclerosis.

Marketed in Japan and Korea for post-stroke complications and bronchial asthma, MN-166 was in-licensed from Kyorin Pharmaceutical to develop and preserve neurons.

Preclinical and clinical studies have demonstrated MN-166’s anti-neuroinflammatory and neuroprotective properties.